Iasis Molecular Sciences Inc. Is an Antifouling, Infection-Prevention Materials Solution Company
Our mission is to improve patient safety and patient outcomes by advancing infection-control solutions for the treatment of complex wounds and associated wound infections, prevention of healthcare associated infections (HAIs), and to enable safe and effective human-environment interactions. To do so, we will leverage our growing portfolio into partnerships, strategic licensing arrangements, and branded products. Our products will provide value added, life improving solutions to at-risk patients and the societal needs of those dependent on interactions with their environment.
Iasis Molecular Sciences has pioneered and patented technologies aimed at preventing medical device infections and treating and preventing infections associated with complex wounds. We have also developed performance coatings for various applications including decorative paints, industrial flooring and marine anti-fouling paints. Iasis Molecular Sciences is on a path to providing value added, life improving solutions to treat or mitigate infections and performance coating solutions to enhance many human-environment interactions.
Iasis Molecular Sciences was founded in 2008 following the discovery that sodium polystyrene sulfonate, a water soluble polymer similar to the FDA-approved therapy Kaexalate, could be used to bind and release antiseptics and provide anti-inflammatory benefits for the treatments of wounds. Later, the concept of using polysulfonates as a delivery platform was leveraged to create a family of formulation modifiers with the ability to render surfaces self-disinfecting.
Iasis Molecular Sciences is located on the Riverpoint Campus in Spokane, WA, within the Innovate Washington incubator. We are situated in the downtown corridor surrounded by Washington State University, Gonzaga University and Eastern Washington University. Iasis Molecular Sciences occupies two fully equipped laboratories, including a wet laboratory, tissue culture, and BSL-2 bacteriology capabilities.